Administration
Administration of SARCLISA
Premedication1
Administer the following premedications prior to SARCLISA infusion to reduce the risk and severity of IRRs.
The above recommended dose of dexamethasone (orally or IV) corresponds to the total dose to be administered only once before infusion as part of the premedication and of the backbone treatment, before SARCLISA and pomalidomide administration.
Administer the recommended premedication agents 15 to 60 minutes prior to starting a SARCLISA infusion.
Preparation and administration1
Infusion rates of SARCLISA administration
Incremental escalation of the infusion rate should be considered only in the absence of IRRs.
75-minute infusion time starting after the second infusion in the absence of IRRs1
- Administer the infusion solution by IV infusion using an IV tubing infusion set (in PE, PVC with or without DEHP, PBD, or PU) with a 0.22-micron in-line filter (PES, polysulfone, or nylon)
- The infusion solution should be administered for a period of time that will depend on the infusion rate (see the table above). Use prepared SARCLISA infusion solution within 48 hours when stored refrigerated at 36°F to 46°F (2°C to 8°C), followed by 8 hours (including the infusion time) at room temperature
- Do not administer SARCLISA infusion solution concomitantly in the same IV line with other agents
SARCLISA Dosing Guide
For detailed dosing and administration information, download the PDF now
Monitoring patients1
Administration adjustments should be made if patients experience the following adverse reactions.
IRRs
- Monitor vital signs frequently during the entire SARCLISA infusion
- For patients with grade 1 or 2 reactions, interrupt SARCLISA infusion and provide appropriate medical support
- If symptoms improve, restart SARCLISA infusion at half of the initial infusion rate, with supportive care as needed, and closely monitor patients
- If symptoms do not recur after 30 minutes, the infusion rate may be increased to the initial rate, and then increased incrementally
- If symptoms do not improve or recur after interruption, permanently discontinue SARCLISA and institute appropriate management
- If a grade 3 or higher IRR occurs, permanently discontinue SARCLISA therapy and institute appropriate medical management
Neutropenia
- Monitor complete blood cell counts periodically during treatment
- Consider the use of antibiotics and antiviral prophylaxis during treatment
- Monitor patients with neutropenia for signs of infection
- If grade 4 neutropenia occurs, consider dose delays until neutrophil count recovery to at least 1.0 × 109/L, and institute supportive care with growth factors, according to institutional guidelines
No dose reduction of SARCLISA is recommended
Interference with serological testing
SARCLISA, an anti-CD38 antibody, may interfere with blood bank serological tests with false-positive reactions in indirect antiglobulin tests (indirect Coombs tests), antibody detection (screening) tests, antibody identification panels, and antihuman globulin crossmatches in patients treated with SARCLISA.
- Conduct blood type and screen tests in patients before the first infusion of SARCLISA
- Consider phenotyping prior to starting treatment with SARCLISA
- If treatment with SARCLISA has already begun, inform the blood bank that the patient is receiving SARCLISA and SARCLISA interference with blood compatibility testing can be resolved using dithiothreitol-treated RBCs
- If an emergency transfusion is required, non–cross-matched ABO/RhD-compatible RBCs can be given as per local blood bank practices
Patient ID
Provide this document to your patients so they can easily inform other HCPs that they are receiving SARCLISA if they need to receive a blood transfusion
Storage and Handling Flashcard
A quick reference tool for SARCLISA storage and handling information